SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Omkar Pharmachem submits newspapers publication

05 Nov 2019 Evaluate

Omkar Pharmachem has informed about submission of copy of newspapers, one in vernacular language and one in English, in which advertisement for convening the Board Meeting, to consider, approve and take on record the Unaudited financial results along with Statement of Assets and Liabilities, Cash Flow Statement and Limited Review Report for the quarter and half year ended on 30th September, 2019, pursuant to regulation 33 of the of the SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 has been given. 

The above information is a part of company’s filings submitted to BSE.

Omkar Pharmachem Share Price

29.50 0.00 (0.00%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×